Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients
Rosa Ayala(Hospital Universitario 12 De Octubre), Carmen Ribera(Research Institute Hospital 12 de Octubre), María‐Teresa Cedena(Hospital Universitario 12 De Octubre), Rosalía Bustelos(Hospital Universitario del Sureste), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Enrique Moreno(Research Institute Hospital 12 de Octubre), Carlos María Gómez-Centurión Jiménez(Universidad Complutense de Madrid)
Cited by 36
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523